Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $566.7 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 1.13% to $566.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, down 17.99% year-over-year, with the annual reading at $566.7 million for FY2025, 1.13% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $566.7 million at 4D Molecular Therapeutics, up from $424.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $629.9 million in Q1 2024, with the low at $240.6 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $399.1 million, with a median of $353.0 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 158.13% in 2024, then decreased 29.81% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $353.5 million in 2021, then dropped by 25.92% to $261.8 million in 2022, then increased by 29.81% to $339.9 million in 2023, then surged by 64.87% to $560.4 million in 2024, then rose by 1.13% to $566.7 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $566.7 million, $424.0 million, and $473.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.